These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 10873048

  • 1. Suppression of primary tumor growth in a mouse model of human neuroblastoma.
    Rowe DH, Huang J, Li J, Manley C, O'Toole KM, Stolar CJ, Yamashiro DJ, Kandel JJ.
    J Pediatr Surg; 2000 Jun; 35(6):977-81. PubMed ID: 10873048
    [Abstract] [Full Text] [Related]

  • 2. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
    Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, O'Toole K, Stolar C, Middlesworth W, Yamashiro DJ, Kandel JJ.
    J Pediatr Surg; 2001 Aug; 36(8):1177-81. PubMed ID: 11479851
    [Abstract] [Full Text] [Related]

  • 3. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, Kadenhe A, New T, Yokoi A, Yamashiro DJ, Kandel JJ, Middlesworth W.
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [Abstract] [Full Text] [Related]

  • 4. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor.
    Kim E, Moore J, Huang J, Soffer S, Manley CA, O'Toole K, Middlesworth W, Stolar CJ, Kandel JJ, Yamashiro DJ.
    J Pediatr Surg; 2001 Feb; 36(2):287-90. PubMed ID: 11172417
    [Abstract] [Full Text] [Related]

  • 5. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.
    Cancer; 2000 Aug 01; 89(3):488-99. PubMed ID: 10931447
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
    Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H.
    Cancer Res; 1995 Nov 15; 55(22):5296-301. PubMed ID: 7585591
    [Abstract] [Full Text] [Related]

  • 7. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
    Melnyk O, Zimmerman M, Kim KJ, Shuman M.
    J Urol; 1999 Mar 15; 161(3):960-3. PubMed ID: 10022734
    [Abstract] [Full Text] [Related]

  • 8. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G.
    Clin Cancer Res; 2000 Sep 15; 6(9):3739-47. PubMed ID: 10999768
    [Abstract] [Full Text] [Related]

  • 9. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y.
    Cancer Res; 2000 Oct 01; 60(19):5565-70. PubMed ID: 11034104
    [Abstract] [Full Text] [Related]

  • 10. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor.
    Rowe DH, Huang J, Kayton ML, Thompson R, Troxel A, O'Toole KM, Yamashiro D, Stolar CJ, Kandel JJ.
    J Pediatr Surg; 2000 Jan 01; 35(1):30-2; discussion 32-3. PubMed ID: 10646769
    [Abstract] [Full Text] [Related]

  • 11. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
    Frischer JS, Huang J, Serur A, Kadenhe-Chiweshe A, McCrudden KW, O'Toole K, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.
    Int J Oncol; 2004 Sep 01; 25(3):549-53. PubMed ID: 15289855
    [Abstract] [Full Text] [Related]

  • 12. [The effect of antibody against vascular endothelial growth factor on tumor growth].
    Wang G, Wang N, Liu T.
    Zhonghua Zhong Liu Za Zhi; 1997 May 01; 19(3):163-6. PubMed ID: 10920886
    [Abstract] [Full Text] [Related]

  • 13. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
    Dagnaes-Hansen F, Rasmussen LM, Tilton R, Denner L, Flyvbjerg A.
    Anticancer Res; 2003 May 01; 23(2B):1625-30. PubMed ID: 12820432
    [Abstract] [Full Text] [Related]

  • 14. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
    Borgström P, Gold DP, Hillan KJ, Ferrara N.
    Anticancer Res; 1999 May 01; 19(5B):4203-14. PubMed ID: 10628376
    [Abstract] [Full Text] [Related]

  • 15. [The effect of antibody against vascular endothelial growth factor (VEGF) on tumor metastasis].
    Wang G, Yang Z, Shou C.
    Zhonghua Zhong Liu Za Zhi; 1997 Nov 01; 19(6):407-9. PubMed ID: 10920868
    [Abstract] [Full Text] [Related]

  • 16. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer.
    Liu CD, Tilch L, Kwan D, McFadden DW.
    J Surg Res; 2002 Jan 01; 102(1):31-4. PubMed ID: 11792148
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth.
    Melnyk O, Shuman MA, Kim KJ.
    Cancer Res; 1996 Feb 15; 56(4):921-4. PubMed ID: 8631034
    [Abstract] [Full Text] [Related]

  • 18. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
    Luo JC, Toyoda M, Shibuya M.
    Cancer Res; 1998 Jun 15; 58(12):2594-600. PubMed ID: 9635584
    [Abstract] [Full Text] [Related]

  • 19. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
    Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh QY.
    Surgery; 2000 Dec 15; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
    [Abstract] [Full Text] [Related]

  • 20. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 15; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.